Acute Hepatitis C in the PROUD pilot study

Similar documents
Professor Sheena McCormack

Dr Monica Desai. MRC Clinical Trials Unit at UCL, London. Science of PrEP. Monica Desai

Supplementary appendix

National HIV self-sampling service. Luis E. Guerra National Programme Manager Sexual Health, Reproductive Health & HIV

Articles. Funding MRC Clinical Trials Unit at UCL, Public Health England, and Gilead Sciences.

Drug development in relation to PrEP and the PROUD study

Dr Huw Price University College London

Initiation of antiretrovirals in HIV/HCV co-infected MSM: Are we too late?

First-line NNRTI to second-line PI/r

Baseline renal function is an independent predictor of death and progression to severe chronic kidney disease

PrEP efficacy the evidence

Mortimer Market Centre, London. Dr Margaret Portman. Date : September 2016

The Context of Sexual Risk Behaviour Among Men Who Have Sex with Men Seeking PrEP, and the Impact of PrEP on Sexual Behaviour

Improving outcomes The UK s achievements in managing and preventing the HIV epidemic and how we should approach public health priorities

Met and unmet health, welfare and social needs of people accessing HIV services Findings from the Positive Voices 2017 survey

HIV prevention: developments since 2012

Professor Caroline Sabin

UK clinicians approach to ART in primary HIV infection; comparison with the BHIVA guidelines

Sexualised drug use: the national picture. Dr Ellen Heinsbroek HIV & STI Dept, National Infection Service, Public Health England

Harnessing molecular technology to inform our understanding of HIV and STI epidemics

CROI 2015: HIV Prevention Updates

National HIV self-sampling service

Trends in transmitted drug resistance to HIV-1 in the UK since 2010

Using anti-hiv drugs for prevention

HIV pre-exposure prophylaxis (PrEP)

Government of Canada Federal AIDS Initiative Milestones

PrEP: Preexposure Prophylaxis to prevent HIV Lisa Pietrusza, BSN, RN FNP-DNP student, University of Pittsburgh Nov. 3, 2017.

Suicide among people diagnosed with HIV in England and Wales compared to the general population

25th Annual Conference of the British HIV Association Bournemouth 2019

Downloaded from:

emtricitabine/tenofovir disoproxil 200mg/245mg film-coated tablets (Truvada ) SMC No. (1225/17) Gilead Sciences Ltd

HIV testing in England and the NICE Quality Standards

HIV testing as the bridge between awareness and acceptance of PrEP among MSM

HIV in primary care. How effective and safe are HIV testing and care in General Practice?

The REACH project: Factors associated with intervals between women s visits to HIV outpatient clinics

Pre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know

Pre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention

Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City

Dr Anatole Menon-Johansson

The HIV Prevention England programme: what s next? Cary James May 2016

Arizona State Office of Rural Health Webinar Series

Scaling up HIV PrEP: How HIV nurses knowledge, attitudes, and behaviors impact PrEP Implementation

Syphilis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

South African Guidelines for the Safe Use of. Dr. Oscar Radebe

Gabriel et al. BMC Infectious Diseases (2018) 18:531

Increase in syphilis testing and detection of early syphilis among men who have sex with men across Australia

Using PrEP as Harm Reduction. Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination

HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017

Combination HIV Prevention

Clinical Commissioning Policy Proposition: Pre-exposure prophylaxis (PrEP) to prevent the acquisition of HIV in adults

Public Health Interventions Advisory Committee (PHIAC)

Time to Test for HIV

Pre-exposure Prophylaxis. Robert M Grant October 2014

UK CAB HIV treatment advocates network

PEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital

PrEP for Women: HIV Prevention in Family Planning Settings

Incidence des IST chez les PrEPeurs

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF

BHIVA Satellite Symposium. Tougher Times: Adapting to Increasing Demand with Declining Resources

and Future Directions

Chlamydia Screening strategy in the UKhow far have we come?

Good care for people with HIV. Rights and Wrongs. Jane Anderson. May 2013

Implementing HIV Screening at Hub and Spoke Sites and Other Drug Treatment Settings

Addressing STIs among MSM: A Clinical and Public Health Update

Engaging Black Men Who have Sex with Men (BMSM) in Los Angeles in HIV Pre-Exposure Prophylaxis (PrEP) Nina Harawa, PhD, MPH Associate Professor

CATIE STATEMENT. on the use of oral pre-exposure prophylaxis (PrEP) as a highly effective strategy to prevent the sexual transmission of HIV

Clinical Education Initiative PRE-EXPOSURE PROPHYLAXIS. Speaker: Antonia Urbina, MD

HIV in Primary Care Shared Care

Why do we need PrEP? Gus Cairns Editor, NAM / Prevention coordinator, EATG Co-chair, PROUD Study

PrEP provision in healthcare settings: UK and France

Pre-exposure prophylaxis (PrEP)

DMRI Drug Misuse Research Initiative

Guidelines for the sexual & reproductive health in PLWH: draft 2016 update

HIV in the United Kingdom

PrEP: Getting to the Tipping Point

HIV Conference Reportback. Carla Gorton HIV, Viral Hepatitis, Sexual Health Coordinator Cairns Sexual Health Service

Pre-exposure Prophylaxis for HIV Prevention

In Silico Pharmacokinetic/Pharmacodynamic Simulation Of Long Acting Tenofovir Injectable Formulation For Pre-exposure Prophylaxis Strategies

Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013

HIV pre-exposure prophylaxis (PrEP)

PrEP Home Checklist v1.0

BHIVA Best of CROI Feedback Meetings BHIVA Best of CROI Feedback Meetings 2012

Pre-Exposure Prophylaxis (PrEP) Stefanie La Manna, PhD, MPH, APRN, FNP-C, AGACNP-BC October 12, 2018

HIV transmission in the UK within Black African communities: how common is it and how do we prevent it? Dr Valerie Delpech

London Chemsex Network Scoping meeting January 2017

NYS PrEP Programming. Lyn Stevens, NP, MS, ACRN Office of the Medical Director, AIDS Institute PrEP Monitoring in NYC and NYS February 19, 2016

THIRD JOINT CONFERENCE OF BHIVA AND BASHH Dr Jamie Frankis. Glasgow Caledonian University. 1-4 April 2014, Arena and Convention Centre Liverpool

The HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE

Modelling HIV Transmission and Treatment for US MSM to Estimate the Impact of HPTN 078 on HIV Incidence

Q and A - the PARTNER Study: new results from PARTNER 2

Dr Melanie Rosenvinge

Boston EMA Ryan White Part A Integrated HIV Prevention and Care Plan. September 8 th, 2016

Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study

PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation. Part 1

HIV in London: A Complexity Challenge

Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention

Population-based PrEP implementation in NSW, Australia

Moving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP?

On the Horizon for Consideration: Biomedical Advances in HIV Prevention

Transcription:

Acute Hepatitis C in the PROUD pilot study Juan Tiraboschi, Liz Brodnicki, Brady Michael, John Saunders, Schembri Gabriel, Mark Roche, Julie Fox on behalf of the PROUD study

PROUD Pilot Study PRe-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay men http://www.proud.mrc.ac.uk/

Background Pre-exposure prophylaxis (PrEP) has proven biological efficacy to reduce the sexual acquisition of HIV 1, but public health benefit is uncertain. Concerns about the effect of PrEP usage on risk behavior and acquisition of other STIs Excluding intravenous transmission, Hepatitis C (HCV) is almost exclusively found in HIV positive MSM. HCV testing is not routine in HIV negative MSM, so it is not included in the PROUD study 1.Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99.. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep. 2012;61:586-9

Methods Past history of STIs is collected at enrolment STI screens are conducted at six monthly intervals, but results from additional routine screens are collected at each visit (three monthly) HCV antibody and raised ALT were not exclusion criteria in PROUD Acute HCV defined as: HCV RNA positive and anti HCV negative (with follow up) HCV Ab/RNA positive with previous negative in 6 months

Results 393 participants enrolled by 31/12/2013 160 (41%) individuals had been tested on one or more occasion for HCV. HCV incidence in our cohort was 5/393:1.3%, and amongst those tested 5/160:3.1%.

Case characteristics Site Randomization ARM Age Time from enrolment to HCV diagnosis (Days) HCV RNA Baseline Indication for HCV Testing Symptoms/ ALT STI since enrolment Brighton Immediate 38 297 311905 Risk behaviour NO Yes Barts Immediate 39 28 11902147 Partner HCV (+) NO No Manchester Deferred 24 64 1684020 Symptoms Jaundice/ Raised ALT Yes STH Immediate 38 29 9003 Partner HCV (+) NO No KLC Deferred 64-28 1,641,554 IDU NO Yes

Time since last HCV negative to HCV diagnosis Case #1 Case #2 Case #3 Case #4 Case #5 days -20 Screening -10 Randomization 10 20 30 40 50 60

Conclusions There was an unexpected number of ahcv cases. HIV prevention studies should consider including HCV testing at baseline and follow-up as part of testing for other STIs. Undiagnosed acute HCV infection in MSM reporting high risk sex is a public health concern. Routine testing of HCV and ALT in the list of routine STIs should be considered for this group.

Acknowledgements (1) Study participants MRC CTU at UCL David Dolling, David Dunn, Mitzy Gafos, Gemma Wood, Liz Brodnicki, Yolanda Collaco- Moraes, Sarah Banbury, Brendan Mauger, Yinka Sowunmi, Christina Chung, Monica Desai, Sheena McCormack HIV & STI Dept, PHE Anthony Nardone, Noel Gill, Sarika Desai, Monica Desai, GUMCAD team, HIV team Clinics Vanessa Apea (Barts Health NHS Trust), Nicola Mackie (St Mary s Hospital), Alan McOwan (56 Dean Street), Amanda Clarke (Claude Nichol Centre), Christine Bowman (Sheffield Teaching Hospitals NHS Foundation Trust), Charles Lacey (York Hospitals NHS Foundation Trust), Gabriel Schembri (Manchester Centre for Sexual Health), Richard Gilson (The Mortimer Market Centre), Ann Sullivan (John Hunter Clinic for Sexual Health), Iain Reeves (Homerton University Hospital NHS Foundation Trust), Michael Brady (Kings College Hospital NHS Foundation Trust), Julie Fox (Guy s and St Thomas s NHS Foundation Trust), Steve Taylor (Heart of England NHS Foundation Trust), Saye Khoo (University of Liverpool)

Acknowledgements (2) Trial Steering Committee Independent members: Mike Adler (Co-Chair), Gus Cairns (Co-Chair), Rob Cookson, Dan Clutterbuck, Claire Foreman, Matthew Williams, Stephen Nicholson, Tariq Sadiq Investigator members: Noel Gill, Anne Johnson, Andrew Phillips, Sheena McCormack, Brian Gazzard Community Engagement Group Clinics: Alan McOwan (56 Dean St), Mark Roche (Brighton) Social media: Darren Clapich (Grindr), Simon Johnson (Gaydar) Press: David Rowlands (Baseline), Robert Fieldhouse (Baseline), Chris O Connor (Baseline), Patrick Cash (QX) Community: Ben McClelland (THT), Matthew Hodson (GMFA), Cary James (THT), Tom Doyle (Mesmac), Yusef Azad (NAT), Justin Harbottle (THT), Roger Pebody (NAM) Academia: Will Nutland (LSHTM) MRC CTU at UCL: Sheena McCormack, Mitzy Gafos, Monica Desai, Annabelle South PHE: Francesa McNeil Gilead Jim Rooney, Rich Clarke, Matt Bosse, Murad Ruf